Literature DB >> 10419529

Multiple ras effector pathways contribute to G(1) cell cycle progression.

H Gille1, J Downward.   

Abstract

The involvement of Ras in the activation of multiple early signaling pathways is well understood, but it is less clear how the various Ras effectors interact with the cell cycle machinery to cause G(1) progression. Ras-mediated activation of extracellular-regulated kinase/mitogen-activated protein kinase has been implicated in cyclin D(1) up-regulation, but there is little extracellular-regulated kinase activity during the later stages of G(1), when cyclin D(1) expression becomes maximal, implying that other effector pathways may also be important in cyclin D(1) induction. We have addressed the involvement of Ras effectors from the phosphatidylinositol (PI) 3-kinase and Ral-GDS families in G(1) progression and compared it to that of the Raf/mitogen-activated protein kinase pathway. PI 3-kinase activity is required for the expression of endogenous cyclin D(1) and for S phase entry following serum stimulation of quiescent NIH 3T3 fibroblasts. Activated PI 3-kinase induces cyclin D(1) transcription and E2F activity, at least in part mediated by the serine/threonine kinase Akt/PKB, and to a lesser extent the Rho family GTPase Rac. In addition, both activated Ral-GDS-like factor and Raf stimulate cyclin D(1) transcription and E2F activity and act in synergy with PI 3-kinase. Therefore, multiple cooperating pathways mediate the effects of Ras on progression through the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10419529     DOI: 10.1074/jbc.274.31.22033

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  92 in total

1.  Ral GTPases contribute to regulation of cyclin D1 through activation of NF-kappaB.

Authors:  D O Henry; S A Moskalenko; K J Kaur; M Fu; R G Pestell; J H Camonis; M A White
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

2.  SRF-dependent gene expression is required for PI3-kinase-regulated cell proliferation.

Authors:  S Poser; S Impey; K Trinh; Z Xia; D R Storm
Journal:  EMBO J       Date:  2000-09-15       Impact factor: 11.598

3.  In vitro and in vivo growth inhibition of human malignant astrocytoma cells by the farnesyltransferase inhibitor B1620.

Authors:  Masanori Kurimoto; Yutaka Hirashima; Hideo Hamada; Hironaga Kamiyama; Shoichi Nagai; Nakamasa Hayashi; Shunro Endo
Journal:  J Neurooncol       Date:  2003-01       Impact factor: 4.130

Review 4.  Preclinical and clinical evaluation of farnesyltransferase inhibitors.

Authors:  Charles Baum; Paul Kirschmeier
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

5.  The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J2 binds to and activates H-Ras.

Authors:  Jose Luis Oliva; Dolores Pérez-Sala; Antonio Castrillo; Natalia Martínez; F Javier Cañada; Lisardo Boscá; José M Rojas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-08       Impact factor: 11.205

6.  The molecular scaffold KSR1 regulates the proliferative and oncogenic potential of cells.

Authors:  Robert L Kortum; Robert E Lewis
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

Review 7.  Integrin signalling and the cellular response to ionizing radiation.

Authors:  Nils Cordes; Viktor Meineke
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

8.  Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT.

Authors:  Amer M Mirza; Stephan Gysin; Nisar Malek; Kei-ichi Nakayama; James M Roberts; Martin McMahon
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

9.  Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells.

Authors:  H Sheng; J Shao; C M Townsend; B M Evers
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

10.  Transcriptional and translational control of ornithine decarboxylase during Ras transformation.

Authors:  Lisa M Shantz
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.